kth.sePublications KTH
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Combinatorial protein engineering for gene therapy and affinity protein applications
KTH, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Protein Science, Protein Technology.ORCID iD: 0009-0002-9799-3493
2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Today, affinity proteins are used as important tools for studying biological functions and play major roles in therapeutic and bioprocessing applications. Many of these applications require protein binders with specific functional properties, such as recognition of different epitopes and protein conformations, modulation of protein activity, or selective targeting of cells and tissues. The work presented in this thesis concentrates on the generation and evaluation of diverse affinity proteins with such distinct functional properties, aiming to support the development of more selective gene therapies and improved bioprocessing technologies. 

Introducing deep-sequencing to phage display workflows, as presented in Paper I and IV, resulted in the identification of Affibody and nanobody binders with distinct kinetic profiles and preferential binding to different target conformations and epitopes. Paper III describes the thorough characterization of two isolated nanobodies for their properties and antagonistic role in protease inhibition, while Paper IV further expands the characterization of nanobody families from the same selection process. 

Aiming to achieve selective gene delivery to specific cells or organs, Paper II describes a modular platform for integration of Affibody targeting ligands into the Adeno-associated virus (AAV) viral surface. These gene delivery vehicles were shown to selectively transduce target-expressing cells in vitro and reduced liver uptake while redirecting the transduction to other organs in vivo. Binders generated in Paper I and IV were also evaluated as targeting ligands on the AAV surface, showing selective transduction capabilities in vitro. Transduction capabilities do not solely depend on target binding, but can be impacted by factors such as binding epitope, kinetics and capsid integration site. This highlights the value of maintaining binder diversity throughout affinity protein development, as the best functional properties cannot always be predicted or screened for. 

A new purification ligand for AAV9 affinity chromatography is presented in Paper V. This Affimer-based ligand showed comparable recovery and product quality to commercial resins, while eluting under milder conditions. 

Lastly, Paper VI evaluates the impact of plasmid purification methods on rAAV production at developmental scale, showing that the choice of buffer and production system can have a major effect on production titers. 

Taken together, the work presented in this thesis contributes to the discovery and application of affinity proteins and highlights their potential to support the development of new therapies and bioprocessing technologies.

Abstract [sv]

Affinitetsproteiner är viktiga verktyg för att studera biologiska funktioner och används flitigt inom både läkemedelsområdet och bioproduktion. Många applikationer kräver proteiner med olika funktionella egenskaper, till exempel att de binder till specifika epitop eller proteinkonformationer, att de kan modulera proteiners aktivitet eller att de selektivt kan binda vissa celler eller organ. Arbetet i den här avhandlingen fokuserar på utvecklingen av nya affinitetsproteiner som har olika funktionella egenskaper, med målet att utveckla mer selektiva genterapier och förbättra relaterade produktions-processer.

Att använda djupsekvensering i samband med fagdisplay-selektioner, som beskivs i Studie I och IV, möjliggjorde identifieringen av affinitetsmolekyler, Affibodies och Nanobodies, med olika kinetikprofiler och preferenser för olika konformationer och epitop hos målproteinerna. Studie III beskriver en djupgående karakterisering av två Nanobodies med avseende på deras egenskaper och hur de påverkade inhibering av proteaser, medan Studie IV utökade karakteriseringen till ytterligare Nanobody-familjer från samma selektions-process. 

I Studie II utvecklades en modulär plattform för selektiv genleverans till specifika celler och organ med hjälp av Adeno-associerade virus (AAVer). Genom att integrera Affibody-molekyler mot specifika cellreceptorer på virusytan var det möjligt att rikta leveransen av gener till celler som uttrycker målreceptorn. AAVerna levererade gener selektivt till celler som uttryckte målproteinet in vitro, och in vivo minskade leverupptaget samtidigt som genleveransen omdirigerades till andra organ. Även bindare framtagna i Studie I och IV utvärderades som målsökande ligander på AAV-ytan, vilket visade liknande resultat in vitro. Transduktionen berodde inte bara på att AAV kunde binda till målproteinet, utan även på faktorer såsom bindningsepitop, kinetikprofiler och integrationsplats på kapsiden. Detta belyser vikten av att bevara mångfald bland affinitetsproteinerna under utvecklingsprocessen, eftersom det är svårt att förutspå vilka egenskaper som är mest gynnsamma.

En ny ligand för rening av AAV9, som är baserad på ytterligare ett affinitetsprotein, Affimer, presenterades i Studie V. Under reningen presterade den lika bra som kommersiella reningsmatriser, men virusen kunde eluera vid mildare pH.

Slutligen gjordes en jämförelse mellan två sätt olika metoder att rena plasmiderna som behövs inom AAV-produktion, där Studie VI visar att val av renings-metod, buffert och produktionssystem påverkar produktionstitrarna.

Sammantaget bidrar arbetet i avhandlingen till utvecklingen av nya affinitetsproteiner med potential att användas inom framtida läkemedel och produktionsprocesser.

Place, publisher, year, edition, pages
Stockholm: KTH Royal Institute of Technology, 2026. , p. 73
Series
TRITA-CBH-FOU ; 2026:47
Keywords [en]
Affinity protein, Phage display, Deep sequencing, AAV, Gene therapy, Affinity chromatography, Affibody, Affimer, Nanobody
Keywords [sv]
Affinitetsprotein, Affibody, Affimer, Nanobody, Fagdisplay, Djupsekvensering, AAV, Genterapi, Affinitetsrening
National Category
Medical Biotechnology
Research subject
Biotechnology
Identifiers
URN: urn:nbn:se:kth:diva-390713ISBN: 978-91-8106-740-8 (print)OAI: oai:DiVA.org:kth-390713DiVA, id: diva2:2110237
Public defence
2026-11-06, Kollegiesalen, via Zoom: https://kth-se.zoom.us/j/64044558400, Brinellvägen 8, Stockholm, 09:30 (English)
Opponent
Supervisors
Note

QC 2026-10-15

Available from: 2026-10-15 Created: 2026-10-14 Last updated: 2026-10-15Bibliographically approved
List of papers
1. Survival of the less fit - directed evolution via deep sequencing enables selection of diverse high affinity proteins
Open this publication in new window or tab >>Survival of the less fit - directed evolution via deep sequencing enables selection of diverse high affinity proteins
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Antibodies and recombinant protein binders are central to biologics, cell therapy and diagnostics. Increasingly, applications demand binders with tailored functionality, such as binding a particular epitope or showing conditional binding and release. This challenges traditional phage display affinity selections, where high affinity binders of very similar binding characteristics are generated. To reach more functional diversity among final clones, the less-fit weaker candidates displaying alternative kinetics, epitope or other characteristics, need to be captured during the selections. Here we present an integrated workflow and software for capturing and maturing such less-fit binders. This is performed by clustering enriched sequence output from rounds of selection in groups of binder families, followed by automated maturation library design for each cluster family of binders used in subsequent phage display selection. We showcase this by selection of Affibody binders against the SARS-CoV-2 S1 protein and human surface receptor Nephrin. Analysis of output clones showed isolation of binders that were not present in the original library. Binders isolated from different focus libraries displayed varying binding kinetics, such as fast-on rate and off-rates, and abilities to bind different epitopes of the addressed targets. When a subset of the Nephrin binders was evaluated as targeting ligands for AAV mediated gene delivery to Nephrin expressing cells, the best transducing clones were not necessarily the highest-affinity binders, demonstrating that affinity alone was insufficient to predict transduction efficiency. We suggest the method to be fit as a general strategy to increase the sampling of functional diversity among binders, allowing for the isolation of candidates with distinct properties, that can be advantageous in different biological and therapeutic contexts.

National Category
Biochemistry Molecular Biology
Identifiers
urn:nbn:se:kth:diva-390647 (URN)
Note

Not duplicate with diva2:1894844

QC 20261013

Available from: 2026-10-13 Created: 2026-10-13 Last updated: 2026-10-14Bibliographically approved
2. A whole body-scale Affibody-based platform for cell-selective in vivo gene therapy
Open this publication in new window or tab >>A whole body-scale Affibody-based platform for cell-selective in vivo gene therapy
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

In vivo gene therapy is limited by inefficient delivery to target tissues and off-target accumulation in critical organs. We describe a whole body-scale retargeting platform for adeno-associated viruses (AAVs) that enables cell-selective DNA delivery through grafting of Affibody affinity proteins onto the capsid. Systematic evaluation identified the VR4 and VR8 loops of virion protein 2 (VP2) as preferred grafting sites, preserving vector integrity, potency, and manufacturability. Six distinct Affibody molecules conferred receptor-dependent infectivity across clinically relevant human receptors, demonstrating platform modularity. A HER2-targeting prodrug strategy enabled selective killing of gastric cancer cells, and dual Affibody integration generated bivalent or bispecific AAVs with enhanced transduction of refractory cell lines, including metastatic adenocarcinoma. In mice, Affibody-AAVs were redirected away from the liver, with 5-fold and 75-fold increases in brain and pancreas uptake relative to wild-type AAV2. Whole-proteome mining across 36 human organs identified organ-enriched receptors as candidates for future cell-selective gene therapies.

National Category
Medical Biotechnology
Identifiers
urn:nbn:se:kth:diva-387221 (URN)
Note

QC 20260824

Available from: 2026-08-21 Created: 2026-08-21 Last updated: 2026-10-14Bibliographically approved
3. Antagonist nanobodies prevent protease inhibition by CD109
Open this publication in new window or tab >>Antagonist nanobodies prevent protease inhibition by CD109
Show others...
2026 (English)In: Journal of Biological Chemistry, ISSN 0021-9258, E-ISSN 1083-351X, Vol. 302, no 3, article id 111187Article in journal (Refereed) Published
Abstract [en]

Cluster of differentiation 109 (CD109) is a cell surface protein found on many human cell types, including keratinocytes, platelets, and T-cells. It is a protease inhibitor of the α-macroglobulin protein superfamily and is reported to affect signaling pathways such as TGFβ and STAT3. Here, we characterized two CD109-specific nanobodies, E1 and B3, that block CD109's interaction with proteases through distinct mechanisms. E1 binds to an epitope on the thiol ester domain of CD109 with high affinity (⁓10−9 M KD), preventing its conjugation to proteases. B3 binds to an epitope near the MG3, MG4, and bait region of CD109 with moderate affinity (⁓10−7 M KD), preventing bait region cleavage. Both mechanisms prevent protease inhibition by CD109. The nanobodies retained their functionalities as Fc fusions, and treatment with B3-Fc prevented the release of membrane-bound CD109 from HEK293F cells by endogenous proteases. These nanobodies provide valuable new tools for investigating CD109's interactions with proteases and may have therapeutic applications in diseases where CD109 plays a pathogenic role.

Place, publisher, year, edition, pages
Elsevier BV, 2026
Keywords
antagonist, antibody, CD109, complement family, inhibition mechanism, protease, protease inhibitor, protein conformation, single-domain antibody, thioester, thiol ester
National Category
Immunology in the Medical Area Cell and Molecular Biology
Identifiers
urn:nbn:se:kth:diva-379835 (URN)10.1016/j.jbc.2026.111187 (DOI)001703786800001 ()41581882 (PubMedID)2-s2.0-105034166695 (Scopus ID)
Note

QC 20260420

Available from: 2026-04-20 Created: 2026-04-20 Last updated: 2026-10-14Bibliographically approved
4. Deep sequencing of an immunized llama library expands discovery of functional CD109 nanobodies and reveals epitope-dependent transduction of nanobody-targeting AAVs
Open this publication in new window or tab >>Deep sequencing of an immunized llama library expands discovery of functional CD109 nanobodies and reveals epitope-dependent transduction of nanobody-targeting AAVs
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Affinity binders that target the same protein in different ways may behave very differently in downstream applications. Thus, protein library selection workflows that enable sampling of many diverse binders are of interest. In this study, a repertoire from a llama immunized with native and protease-cleaved CD109, a disease-associated alpha-macroglobulin protease inhibitor, was cloned and subjected to phage-display selection for isolation of target-specific nanobodies binding different CD109 conformations. Oxford Nanopore sequencing of each selection round followed by sequence-guided clustering identified 1591 CDR3 families, which were depleted during selection, leaving only eight families after the final round. Isolation of single clones using traditional workflows allowed for detection of a subset of the binders present in the library, and the deep sequencing workflow expanded the pool of potential candidates. Clones from ten CDR3 families were selected for characterization and these nanobodies displayed diverse properties, including recognition of native and/or cleaved CD109, affinities (KD values) of 1-200nM and binning to three epitope groups. These groups correlated with their observed antagonistic effects on CD109 protease inhibition. Four of the clones, representing different families of binders, were displayed on adeno-associated virus 2 capsids as targeting ligands for selective gene delivery to cells expressing CD109. Transduction efficiency of CD109-expressing cells could be attributed to insertion site, or epitope and conformation preference of the binder rather than affinity alone. Altogether, results demonstrate that binder characteristics are important to consider for successful use in gene therapy and thus, the utility of high-throughput sequencing guided selections to identify a broad affinity binder repertoire for drug discovery.

Keywords
Deep sequencing, phage display, CD109, nanobody, protease inhibition, AAV, gene therapy
National Category
Medical Biotechnology
Research subject
Biotechnology
Identifiers
urn:nbn:se:kth:diva-390556 (URN)
Note

QC 20261012

Available from: 2026-10-12 Created: 2026-10-12 Last updated: 2026-10-14Bibliographically approved
5. A serotype-selective Affimer ligand for the affinity capture of AAV9
Open this publication in new window or tab >>A serotype-selective Affimer ligand for the affinity capture of AAV9
Show others...
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Adeno-associated virus serotype 9 (AAV9) is a key vector for gene therapies targeting the central nervous system, and its high dose requirements place substantial demands on its bioproduction. Current downstream processes typically rely on affinity capture of AAV9 using camelid-derived or synthetic peptide ligands that release the capsid at low pH, conditions linked to loss of capsid integrity, potency and potential sensitivity in column regeneration. Here we present a serotype-selective AAV9 capture ligand based on the small 13 kDa Affimer phytocystatin scaffold. A picomolar affinity AAV9 Affimer was isolated by phage display against assembled AAV9 capsids with no detectable binding to AAV2, AAV5 or AAV8. Following screening of an Escherichia coli expression vector panel, varying promoter and leader sequence, T7-driven intracellular expression was selected for scale-up. Scalability was shown in a 10 L fed-batch process that produced 24 g of Affimer ligand. Polished binder was coupled to an agarose-based adsorbent and benchmarked against the commercial AVIPure AAV9 and POROS CaptureSelect AAV9 columns. The Affimer column recovered a similar total capsid amount compared to the commercial columns (4.9E+13 compared to 5.2E+13 and 4.7E+13) and reduced host cell proteins and DNA to below 1% in each elution fraction. AAV9 was released from the Affimer column at pH 5, whereas AVIPure required pH 3 and CaptureSelect eluted across pH 5 and pH 4. The purified vectors had comparable full capsid content (40 to 46%) and transduced HEK293F cells with similar efficiency (36 to 38% GFP-positive cells). Our AAV9 Affimer allows for a high yield microbial production process and serotype-selective capture with retained potency under milder elution conditions with potential for industrial applications.

Keywords
Gene therapy, Adeno-associated virus, affinity chromatography, purification ligand, Affimer
National Category
Industrial Biotechnology
Research subject
Biotechnology
Identifiers
urn:nbn:se:kth:diva-390558 (URN)
Note

QC 20261012

Available from: 2026-10-12 Created: 2026-10-12 Last updated: 2026-10-14Bibliographically approved
6. Automated plasmid purification system enables increased AAV production
Open this publication in new window or tab >>Automated plasmid purification system enables increased AAV production
Show others...
2026 (English)In: New Biotechnology, ISSN 1871-6784, E-ISSN 1876-4347, Vol. 93, p. 143-154Article in journal (Refereed) Published
Abstract [en]

Gene therapies are transforming modern medicine, with adeno-associated virus (AAV) being the most used vector for delivery. High manufacturing costs however continue to limit drug discovery, clinical development, and patient access. Plasmid DNA (pDNA) has been identified as a critical bottleneck in AAV development and small-scale production. In this study, we compared conventional manual plasmid purification kits with a scalable, automated purification system across Maxi, Mega, and Giga scales. Time savings increased with purification scale, e.g., when purifying 4 plasmid samples at Giga scale (10 mg column plasmid capacity), 8 h of active time was saved using the automated system and total time was cut from almost 10 h to 5 h, although with generally lower yields (3–67% lower) and higher endotoxin levels. Both purification methods produced comparable AAV9 titres using standard PEI-based transfection of HEK293F cells. Surprisingly the AAV-MAX production system, plasmids purified by the automated method generated 14-fold higher titres than manually purified plasmids (3.2 ×10 ¹¹ vg/ml vs. 2.3 ×10 ¹⁰ vg/ml, respectively). Further analyses, including single and triple plasmid transfections and dynamic light scattering, revealed that the elution buffer used in the automated system formed larger pDNA transfection complexes in the AAV-MAX system and resulted in increased transfection efficiency. These findings provide insights that extend beyond AAV manufacturing, highlighting opportunities to optimise the transient production of other biologics and further improvement of plasmid preparation methods.

Place, publisher, year, edition, pages
Elsevier BV, 2026
Keywords
Adeno-associated virus, automation, drug development, gene therapy, plasmid, production, purification
National Category
Molecular Biology Microbiology in the Medical Area Embedded Systems
Identifiers
urn:nbn:se:kth:diva-378535 (URN)10.1016/j.nbt.2026.02.008 (DOI)001713247400001 ()41786127 (PubMedID)2-s2.0-105032051613 (Scopus ID)
Note

QC 20260325

Available from: 2026-03-25 Created: 2026-03-25 Last updated: 2026-10-14Bibliographically approved

Open Access in DiVA

Thesis(9318 kB)34 downloads
File information
File name FULLTEXT03.pdfFile size 9318 kBChecksum SHA-512
073e6b5e885a42235d1af3e7d2d830fc4d2e59fcad8761594a36f46db9ce00bdb1f8ca59fb370950632bf195b70033cc8fb7f6e4f9e247b5f9884fae44bfa6c3
Type summaryMimetype application/pdf

Authority records

Rönning, Sanne

Search in DiVA

By author/editor
Rönning, Sanne
By organisation
Protein Technology
Medical Biotechnology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

isbn
urn-nbn

Altmetric score

isbn
urn-nbn
Total: 138 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf